BioSpace News Archive

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, has been recognized as a winner of the 2021 Bay Area Best Places to Work, an awards program presented by the San Francisco Business Times and the Silicon Valley Business Journal.

Omeros Corporation, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases and central nervous system disorders, announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2021, which include:

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial results for the quarter ending March 31, 2021 and updates on the Company’s key pipeline developments, business operations, and upcoming milestones.

ZERION Pharma, a Danish pharmaceutical company, elected two new members Dr. Torsten Goesch and Dr. Lars Lykke Thomsen to join its board of directors at the annual general meeting held on May 6, 2021.

ECI Pharmaceuticals, LLC (ECI) today announced that it has entered into an exclusive U.S. agreement with Qilu Pharmaceutical Co., Ltd. (Qilu) to manage the sales, marketing, and distribution for the therapeutically equivalent generic of Cialis®, with strengths of 2.5mg, 5mg, 10mg, and 20mg tablets.

Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, reported financial results for the first quarter ended March 31, 2021.

Second Phase of Commercialization Advances with the Addition of Multiple Limited Release Customers

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2021 operating and financial results.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Dr. Jenny (Yajin) Ni as its Chief Technology Officer (CTO).

Surgalign Spine Technologies, a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, reported operating results for the first quarter of 2021.